The study of dapagliflozin (sodium glucose cotransporter 2 inhibitor) to verify the efficacy of combination therapy in Japanese patients with type 2 diabetes
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2017
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms DISCOVERY study
- 10 Apr 2017 Status changed from active, no longer recruiting to completed.
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 14 Oct 2014 New trial record